Insider Selling: CAMP4 Therapeutics (NASDAQ:CAMP) Director Sells $144,081.00 in Stock

Key Points

• Director Andrew Schwab sold 32,018 CAMP shares at an average price of $4.50, generating $144,081. He retained 2,433,280 shares, with the transaction reducing his position by 1.30%.
• CAMP shares traded at $4.48, within a 52-week range of $1.41 to $7.75. The company reported a quarterly loss of $0.58 per share, missing analyst expectations by $0.34, on revenue of $1.78 million.
• Analyst sentiment remains generally positive, with seven Buy ratings, one Hold, and one Sell; the consensus rating is Moderate Buy with a $9.56 price target.

CAMP4 Therapeutics Corporation (NASDAQ:CAMP - Get Free Report) Director Andrew Schwab sold 32,018 shares of the firm's stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $4.50, for a total transaction of $144,081.00. Following the completion of the transaction, the director directly owned 2,433,280 shares in the company, valued at $10,949,760. This represents a 1.30% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

CAMP4 Therapeutics Price Performance

CAMP stock traded up $0.02 during trading hours on Friday, reaching $4.48. The stock had a trading volume of 126,663 shares, compared to its average volume of 183,971. CAMP4 Therapeutics Corporation has a fifty-two week low of $1.41 and a fifty-two week high of $7.75. The stock has a 50-day simple moving average of $4.11 and a 200 day simple moving average of $4.33. The stock has a market capitalization of $281.12 million, a PE ratio of -1.93 and a beta of 0.22.

CAMP4 Therapeutics (NASDAQ:CAMP - Get Free Report) last announced its quarterly earnings results on Thursday, August 13th. The Wireless communications provider reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.34). CAMP4 Therapeutics had a negative net margin of 2,543.74% and a negative return on equity of 252.79%. The company had revenue of $1.78 million during the quarter. On average, sell-side analysts forecast that CAMP4 Therapeutics Corporation will post -0.59 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on CAMP shares. JPMorgan Chase & Co. raised shares of CAMP4 Therapeutics from a "neutral" rating to an "overweight" rating and boosted their target price for the stock from $5.00 to $9.00 in a research report on Tuesday, June 16th. Weiss Ratings raised CAMP4 Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Friday, August 14th. Chardan Capital set a $6.50 price target on shares of CAMP4 Therapeutics and gave the stock a "buy" rating in a research note on Wednesday, June 10th. UBS Group set a $15.00 price objective on shares of CAMP4 Therapeutics in a research note on Friday, August 14th. Finally, Piper Sandler restated an "overweight" rating and issued a $15.00 target price (up from $12.00) on shares of CAMP4 Therapeutics in a research note on Friday, August 14th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $9.56.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of CAMP. Bridgeway Capital Management LLC bought a new position in shares of CAMP4 Therapeutics during the second quarter worth about $36,000. China Universal Asset Management Co. Ltd. acquired a new stake in CAMP4 Therapeutics in the 4th quarter valued at $61,000. Jefferies Financial Group Inc. purchased a new position in CAMP4 Therapeutics in the 4th quarter valued at approximately $70,000. Bank of America Corp DE bought a new position in CAMP4 Therapeutics during the 2nd quarter valued at approximately $78,000. Finally, OMERS ADMINISTRATION Corp purchased a new position in shares of CAMP4 Therapeutics during the fourth quarter valued at approximately $115,000.

CAMP4 Therapeutics Company Profile

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source